|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...1617181920212223242526...4950» |
- |||||||||| nevirapine / Generic mfg.
New P3 trial: Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women (clinicaltrials.gov) - Jul 8, 2014
P3, N=2648, Completed, Sponsor: Boehringer Ingelheim
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P1 trial: Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected Women (clinicaltrials.gov) - Jul 8, 2014
P1, N=14, Completed, Sponsor: Boehringer Ingelheim
- nevirapine / Generic mfg., amprenavir / Generic mfg., abacavir / Generic mfg.
New P1 trial: Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults (clinicaltrials.gov) - Jul 8, 2014
P1, N=8, Terminated, Sponsor: Boehringer Ingelheim
- Trial primary completion date: Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study) (clinicaltrials.gov) - Jul 4, 2014
P=N/A, N=246, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Dec 2013 --> Dec 2014
- Enrollment closed, Trial primary completion date: Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study) (clinicaltrials.gov) - Jul 4, 2014
P=N/A, N=246, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Dec 2013 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Dec 2014
- ||| censavudine (TPN-101) / Transposon Therap, Yale University
Enrollment closed: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (clinicaltrials.gov) - Jul 1, 2014
P2b, N=300, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Dec 2014 Recruiting --> Active, not recruiting
- ||| Rukobia (fostemsavir) / ViiV Healthcare
Enrollment closed: HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections (clinicaltrials.gov) - Jul 1, 2014
P2b, N=250, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Aptivus (tipranavir) / Boehringer Ingelheim
Trial completion: Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST) (clinicaltrials.gov) - Jun 30, 2014
P3, N=630, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, Trial initiation date: Longitudinal Study of Ocular Complications of AIDS (LSOCA) (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=2392, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Active, not recruiting --> Completed Initiation date: Aug 1999 --> Aug 1998 | Recruiting --> Completed
- Enrollment closed: LINC: Linking Infectious and Narcology Care in Russia (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=350, Active, not recruiting, Sponsor: Boston Medical Center
Initiation date: Aug 1999 --> Aug 1998 | Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| emtricitabine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Monotherapy: DREAM: Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients (clinicaltrials.gov) - Jun 27, 2014
P2/3, N=420, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Trial initiation date: Longitudinal Study of Ocular Complications of AIDS (LSOCA) (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=2392, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Active, not recruiting --> Completed Recruiting --> Completed | Initiation date: Aug 1999 --> Aug 1998
- | Enrollment closed: MAINTAIN: Micronutrients and Antioxidants in HIV Infection (clinicaltrials.gov) - Jun 24, 2014
P2/3, N=218, Active, not recruiting, Sponsor: Ottawa Hospital Research Institute
Recruiting --> Completed | Initiation date: Aug 1999 --> Aug 1998 Recruiting --> Active, not recruiting
- erlotinib / Generic mfg.
Trial primary completion date, Surgery, Metastases: Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection (clinicaltrials.gov) - Jun 19, 2014
P1, N=48, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Sep 2016
- nevirapine / Generic mfg.
New P3 trial: Nevirapine Dosing in Neonates for Prophylaxis of Mother-to-Child-Transmission (MTCT) of HIV Infection (clinicaltrials.gov) - Jun 19, 2014
P3, N=24, Recruiting, Sponsor: The Hospital for Sick Children
- |||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial primary completion date: INSIGHT: An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (clinicaltrials.gov) - Jun 18, 2014
P3, N=163, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Trial primary completion date: Jun 2016 --> Sep 2016 Trial primary completion date: Jun 2014 --> Mar 2014
- tenofovir vaginal gel (GS-1278 gel) / Gilead, CONRAD
Trial primary completion date: Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection (clinicaltrials.gov) - Jun 18, 2014
P3, N=2900, Active, not recruiting, Sponsor: CONRAD
Trial primary completion date: Jun 2014 --> Mar 2014 Trial primary completion date: May 2014 --> Aug 2014
- | Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J
New P2 trial: Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis (clinicaltrials.gov) - Jun 18, 2014
P2, N=132, Not yet recruiting, Sponsor: PATH
- | tenofovir vaginal gel (GS-1278 gel) / Gilead, CONRAD
Enrollment closed, Trial primary completion date: Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection (clinicaltrials.gov) - Jun 18, 2014
P3, N=2900, Active, not recruiting, Sponsor: CONRAD
Trial primary completion date: May 2014 --> Aug 2014 Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Aug 2014
- ||| nevirapine / Generic mfg.
Trial completion, Adherence: Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=398, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Aug 2014 Active, not recruiting --> Completed
- |||| Prezista (darunavir) / J&J
Trial completion: An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects. (clinicaltrials.gov) - Jun 18, 2014
P2, N=555, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - Jun 17, 2014
P3, N=538, Recruiting, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment closed: imPACT: Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=400, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Vocabria (cabotegravir oral) / ViiV Healthcare
Trial completion: Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction (clinicaltrials.gov) - Jun 17, 2014
P1, N=42, Completed, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Zorbtive (somatropin) / EMD Serono
Trial completion: Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients (clinicaltrials.gov) - Jun 15, 2014
P3, N=569, Completed, Sponsor: EMD Serono
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection (clinicaltrials.gov) - Jun 13, 2014
P3, N=300, Active, not recruiting, Sponsor: Gilead Sciences
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- | Phase classification: A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects (clinicaltrials.gov) - Jun 12, 2014
P4, N=480, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P4
- Isentress (raltegravir) / Merck (MSD)
Phase classification: Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=20, Completed, Sponsor: University of Alabama at Birmingham
Phase classification: P=N/A --> P4 Phase classification: P4 --> P=N/A
- Phase classification: Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs (clinicaltrials.gov) - Jun 12, 2014
P2, N=96, Completed, Sponsor: New York University School of Medicine
Phase classification: P4 --> P=N/A Phase classification: P=N/A --> P2
- | modafinil / Generic mfg.
Trial completion: Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS (clinicaltrials.gov) - Jun 8, 2014
P4, N=115, Completed, Sponsor: New York State Psychiatric Institute
Phase classification: P=N/A --> P2 Active, not recruiting --> Completed
- erlotinib / Generic mfg.
Enrollment change, Surgery, Metastases: Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection (clinicaltrials.gov) - Jun 8, 2014
P1, N=48, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=36 --> 48
- Trial completion: Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs (clinicaltrials.gov) - Jun 8, 2014
P2, N=96, Completed, Sponsor: New York University School of Medicine
N=36 --> 48 Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: Effect of Antacids on the Pharmacokinetics of Raltegravir (clinicaltrials.gov) - Jun 5, 2014
P=N/A, N=17, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed N=24 --> 17
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Effect of Antacids on the Pharmacokinetics of Raltegravir (clinicaltrials.gov) - Jun 5, 2014
P=N/A, N=17, Completed, Sponsor: University of Colorado, Denver
N=24 --> 17 Recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects (clinicaltrials.gov) - Jun 4, 2014
P1, N=12, Completed, Sponsor: ViiV Healthcare
Recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Transfusion Infections Pediatric Prospective Study (TRIPPS) (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=600, Completed, Sponsor: Children's Research Institute
Active, not recruiting --> Completed Trial primary completion date: Mar 2006 --> Apr 2013
- Trial primary completion date: Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients (clinicaltrials.gov) - Jun 3, 2014
P1, N=33, Active, not recruiting, Sponsor: Sangamo Biosciences
Trial primary completion date: Mar 2006 --> Apr 2013 Trial primary completion date: May 2014 --> Dec 2014
- Enrollment closed: IMEDI: HIV and Drug Use in Georgian Women (clinicaltrials.gov) - Jun 3, 2014
P=N/A, N=128, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: May 2014 --> Dec 2014 Recruiting --> Active, not recruiting
- Trial completion: Prevention for Positives: An RCT Among Vietnamese HIV-positive IDU (clinicaltrials.gov) - Jun 3, 2014
P=N/A, N=2175, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- temazepam / Generic mfg.
New P4 trial, Review: Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia (clinicaltrials.gov) - Jun 1, 2014
P4, N=46, Completed, Sponsor: Duke University
- New P1 trial: Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects (clinicaltrials.gov) - Jun 1, 2014
P1, N=12, Recruiting, Sponsor: University of Pennsylvania
- Enrollment open: ANRS ECHAM;ECHAM: Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=560, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial primary completion date: COMO: Cognition Study With HIV+ Patients (CTNPT 015) (clinicaltrials.gov) - May 29, 2014
P0, N=25, Recruiting, Sponsor: Marie-Jos
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2014 --> Nov 2015
- fosamprenavir / Generic mfg.
Trial primary completion date: FOSTER-C: HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir (clinicaltrials.gov) - May 28, 2014
P4, N=42, Completed, Sponsor: Fundacion SEIMC-GESIDA
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Oct 2013 --> Jun 2013
- fosamprenavir / Generic mfg.
Trial completion date: FOSTER-C: HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir (clinicaltrials.gov) - May 28, 2014
P4, N=42, Completed, Sponsor: Fundacion SEIMC-GESIDA
Trial primary completion date: Oct 2013 --> Jun 2013 Trial completion date: Nov 2013 --> Jun 2013
- | fosamprenavir / Generic mfg.
Enrollment change: FOSTER-C: HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir (clinicaltrials.gov) - May 28, 2014
P4, N=42, Completed, Sponsor: Fundacion SEIMC-GESIDA
Trial completion date: Nov 2013 --> Jun 2013 N=72 --> 42
- | fosamprenavir / Generic mfg.
Trial completion: FOSTER-C: HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir (clinicaltrials.gov) - May 28, 2014
P4, N=42, Completed, Sponsor: Fundacion SEIMC-GESIDA
N=72 --> 42 Recruiting --> Completed
- || Isentress (raltegravir) / Merck (MSD)
Enrollment change: Isentress Re-examination Study (MK-0518-115) (clinicaltrials.gov) - May 28, 2014
P=N/A, N=996, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed N=3000 --> 996
- |||||| Isentress (raltegravir) / Merck (MSD)
Enrollment open, Combination therapy: onceMRK: Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA (clinicaltrials.gov) - May 28, 2014
P3, N=750, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=3000 --> 996 Not yet recruiting --> Recruiting
- ||| Isentress (raltegravir) / Merck (MSD)
Trial completion: Isentress Re-examination Study (MK-0518-115) (clinicaltrials.gov) - May 28, 2014
P=N/A, N=996, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Recruiting --> Completed